Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

Novo Nordisk is continuing its push into genetic ... technology in the development of two base-editing therapies in rare genetic diseases. The deal covers up to five more targets in rare and ...

Novo Nordisk and NanoVation will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases. NanoVation’s lcLNP technology has demonstrated the ability ...

Novo Nordisk's weight-loss drugs ... the name's PEG ratio is 2.1 just slightly above the sector average of two. PEG is a measure of valuation that takes into account future growth expectations.

Korro will advance up to two programs through preclinical development after which point Novo Nordisk could further advance the programs through clinical studies. Korro Bio NewsMORE Related Stocks ...

Ahead of a Senate hearing next week at which Novo Nordisk’s CEO has been called to testify, health committee chair Bernie Sanders is keeping the heat on the company. Since April of this year ...

Shares of Novo Nordisk NVO gained 4.2% on Sept. 11 after the company presented encouraging detailed efficacy data from the early-stage study of its new, investigational oral obesity pill ...

Novo Nordisk is developing a weight loss pill. In the early stage trial, Novo evaluated how patients fared when taking one or two 50 mg amycretin pills a day or an inert placebo. Patients taking ...

DSV A/S’s new acquisition, the $15.9 billion takeover of DB Schenker, will almost double the freight company’s sales, making it Denmark’s second-largest firm by that measure and pushing Novo ...

Korro will advance up to two programs through preclinical development after which point Novo Nordisk could further advance the programs through clinical studies. Korro is a biopharmaceutical ...